ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has signed an exclusive agreement with Novo Nordisk Inc. to market Prandin® (repaglinide). Under the terms of the agreement, Sciele will exclusively market Prandin® and, upon approval by the U.S. Food & Drug Administration (FDA), PrandiMet® (the name submitted to the FDA for a repaglinide/metformin fixed dose combination tablet) to physicians in the U.S., and will have the right of first refusal to obtain marketing rights in the U.S. to other Novo Nordisk products containing repaglinide, the active pharmaceutical ingredient in both Prandin® and PrandiMet®.
